|
42 Companies |
|
59 Products |
|
59 Products |
|
53 Mechanisms of Action |
|
1 Trial |
|
228 News |
|
| «12345» |
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Enrollment open: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Mar 15, 2014
P2, N=33, Recruiting, Sponsor: Bruno C. Medeiros
Not yet recruiting --> Recruiting
- | Istodax (romidepsin) / Astellas, BMS
Trial completion: Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders (clinicaltrials.gov) - Feb 22, 2014
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Combination therapy: Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 22, 2014
P1, N=100, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed Active, not recruiting --> Completed
- ||||||| Onrigin (laromustine) / Vion
Trial completion: Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 22, 2014
P3, N=420, Completed, Sponsor: Vion Pharmaceuticals
Active, not recruiting --> Completed Suspended --> Completed
- | tanespimycin (BMS-722782) / BMS
Trial completion: Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Feb 22, 2014
P1, N=42, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: XK469R in Treating Patients With Refractory Hematologic Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=60, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Completed
- | arsenic trioxide / Generic mfg., cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial completion: Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 22, 2014
P1, N=61, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed Active, not recruiting --> Completed
- | Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion: Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Recruiting --> Completed
- | Triapine (3-AP) / Vion, Northwestern University
Trial completion: 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed No longer recruiting --> Completed
- | Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion: COG-AAML03P1: Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy (clinicaltrials.gov) - Feb 22, 2014
P2, N=350, Completed, Sponsor: Children's Oncology Group
No longer recruiting --> Completed No longer recruiting --> Completed
- | cytarabine / Generic mfg., irinotecan / Generic mfg.
Trial completion: Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed, Sponsor: Roswell Park Cancer Institute
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 22, 2014
P2, N=125, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: SWOG-E2998: flt3L in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, NN1213 / Novo Nordisk, Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion: Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Completed No longer recruiting --> Completed
- | topotecan / Generic mfg., carboplatin / Generic mfg., fludarabine IV / Generic mfg.
Trial completion, Metastases: Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P1, N=31, Completed, Sponsor: Case Comprehensive Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=7, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical protocol, Trial completion: Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | thioguanine / Generic mfg.
Trial completion: Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P3, N=254, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Amdray (valspodar) / Novartis
Trial completion: Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 19, 2014
P3, N=640, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Amdray (valspodar) / Novartis
Trial completion: Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=410, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | thioguanine / Generic mfg.
Trial completion: Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P3, N=880, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P2, N=280, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
No longer recruiting --> Completed Active, not recruiting --> Completed
- | thioguanine / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 13, 2014
P=N/A, N=20, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- || Biomarker, Enrollment change: Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 12, 2014
P=N/A, N=250, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Recruiting N=200 --> 250
- ||| Biomarker, Enrollment open: Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 12, 2014
P=N/A, N=250, Recruiting, Sponsor: Children's Oncology Group
N=200 --> 250 Active, not recruiting --> Recruiting
- Trial initiation date: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 6, 2014
P1, N=30, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Recruiting Initiation date: Jul 2013 --> Feb 2014
- Enrollment open: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 6, 2014
P1, N=30, Recruiting, Sponsor: Stanford University
Initiation date: Jul 2013 --> Feb 2014 Not yet recruiting --> Recruiting
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
New P1 trial: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 28, 2014
P1, N=19, Not yet recruiting, Sponsor: Bruno C. Medeiros
- alvocidib (DSP-2033) / Sumitomo Pharma
Enrollment closed: Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 14, 2014
P2, N=165, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Biomarker, Trial completion: S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 12, 2014
P=N/A, N=357, Completed, Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Ninlaro (ixazomib) / Takeda
New P2 trial: Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 6, 2014
P2, N=16, Recruiting, Sponsor: Bruno C. Medeiros
- | Synribo (omacetaxine mepesuccinate) / Teva
New P2 trial: Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 5, 2014
P2, N=37, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
New P2 trial: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Dec 22, 2013
P2, N=33, Recruiting, Sponsor: Bruno C. Medeiros
- bortezomib / Generic mfg.
Enrollment change, IO biomarker: Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 17, 2013
P2, N=52, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=90 --> 52
- bortezomib / Generic mfg.
Enrollment closed, IO biomarker: Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 17, 2013
P2, N=52, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=90 --> 52 Completed --> Active, not recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 16, 2013
P3, N=0, Completed, Sponsor: Medical Research Council
Completed --> Active, not recruiting Active, not recruiting --> Completed
- alvocidib (DSP-2033) / Sumitomo Pharma
Enrollment closed: Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 5, 2013
P2, N=111, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- dexamethasone / Generic mfg.
Trial termination: Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate (clinicaltrials.gov) - Nov 17, 2013
P1, N=15, Terminated, Sponsor: Rutgers, The State University of New Jersey
Recruiting --> Active, not recruiting Completed --> Terminated; Replaced by another study
- dexamethasone / Generic mfg.
Enrollment change: Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate (clinicaltrials.gov) - Nov 17, 2013
P1, N=15, Terminated, Sponsor: Rutgers, The State University of New Jersey
Completed --> Terminated; Replaced by another study N=24 --> 15
- Enrollment change: Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy (clinicaltrials.gov) - Nov 6, 2013
P2, N=4, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
N=24 --> 15 N=18 --> 4
- Torisel (temsirolimus) / Pfizer
Trial completion: Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 3, 2013
P2, N=60, Completed, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
N=18 --> 4 Active, not recruiting --> Completed
- metformin / Generic mfg., cytarabine / Generic mfg.
Enrollment open: Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML (clinicaltrials.gov) - Oct 27, 2013
P1, N=28, Recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| cytarabine / Generic mfg., clofarabine / Generic mfg.
Enrollment closed, Combination therapy: Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 21, 2013
P1/2, N=74, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- | thioguanine / Generic mfg.
Trial completion: Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Oct 16, 2013
P3, N=2000, Completed, Sponsor: Leukemia Research Fund
Completed --> Active, not recruiting Active, not recruiting --> Completed
- imatinib / Generic mfg., cladribine / Generic mfg., cytarabine / Generic mfg.
Trial completion, Combination therapy: Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Oct 13, 2013
P1, N=18, Completed, Sponsor: University of Rochester
Active, not recruiting --> Completed Recruiting --> Completed
- cytarabine / Generic mfg., decitabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Enrollment change: Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS (clinicaltrials.gov) - Oct 8, 2013
P2, N=7, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Completed N=38 --> 7
- cytarabine / Generic mfg., decitabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial completion: Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS (clinicaltrials.gov) - Oct 8, 2013
P2, N=7, Completed, Sponsor: Fred Hutchinson Cancer Research Center
N=38 --> 7 Active, not recruiting --> Completed
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion: Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 6, 2013
P2, N=25, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Terminated --> Completed
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial termination, Combination therapy, Epigenetic controller, Metastases: Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 17, 2013
P1, N=44, Terminated, Sponsor: National Cancer Institute (NCI)
Terminated --> Completed Active, not recruiting --> Terminated